Anaptysbio Stock Analysis

AnaptysBio Stock Analysis Notes

About 94.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.82. AnaptysBio had not issued any dividends in recent years. AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. Anaptysbio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. For more info on AnaptysBio please contact the company at 858 362 6295 or go to https://www.anaptysbio.com.

AnaptysBio Investment Alerts

AnaptysBio Largest EPS Surprises

View All Earnings Estimates

AnaptysBio Environmental, Social, and Governance (ESG) Scores

AnaptysBio Stock Institutional Investors

Note, although AnaptysBio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

AnaptysBio Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.55 B.

AnaptysBio Profitablity

The company has Profit Margin (PM) of (0.5) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45.

Management Efficiency

AnaptysBio has return on total asset (ROA) of (0.0423) % which means that it has lost $0.0423 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.0802) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 13, 2026, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.25. At present, AnaptysBio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.72, whereas Total Assets are forecasted to decline to about 369.2 M.

Technical Drivers

As of the 13th of February 2026, AnaptysBio shows the risk adjusted performance of 0.1271, and Mean Deviation of 2.68. AnaptysBio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

AnaptysBio Price Movement Analysis

AnaptysBio Insider Trading Activities

AnaptysBio Outstanding Bonds

AnaptysBio Predictive Daily Indicators

AnaptysBio Corporate Filings

AnaptysBio Forecast Models

AnaptysBio's time-series forecasting models are one of many AnaptysBio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AnaptysBio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

AnaptysBio Bond Ratings

AnaptysBio financial ratings play a critical role in determining how much AnaptysBio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for AnaptysBio's borrowing costs.

AnaptysBio Debt to Cash Allocation

AnaptysBio currently holds 369.46 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. AnaptysBio has a current ratio of 22.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AnaptysBio's use of debt, we should always consider it together with its cash and equity.

AnaptysBio Total Assets Over Time

AnaptysBio Assets Financed by Debt

The debt-to-assets ratio shows the degree to which AnaptysBio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

AnaptysBio Debt Ratio

72.0

It appears most of the AnaptysBio's assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the AnaptysBio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of AnaptysBio, which in turn will lower the firm's financial flexibility.

AnaptysBio Corporate Bonds Issued

AnaptysBio Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how AnaptysBio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AnaptysBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AnaptysBio. By using and applying AnaptysBio Stock analysis, traders can create a robust methodology for identifying AnaptysBio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AnaptysBio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AnaptysBio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

AnaptysBio stock analysis indicators help investors evaluate how AnaptysBio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AnaptysBio shares will generate the highest return on investment. By understating and applying AnaptysBio stock analysis, traders can identify AnaptysBio position entry and exit signals to maximize returns.

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.